Big U.S. corporations are benefiting from a "new exceptionalism," allowing them to skip out on their domestic tax bills, The Washington Post says.» Read More
This company has heart, Cramer says. Find out how BSX fought its way off the operating table.
Rob Morgan of Clermont Wealth Strategies got some encouragement from President Obama's remarks about stimulus and recovery, but not enough to make him bullish on financials. That's not to say he's completely down on stocks.
It’s easy to like a company that, even in this environment, is focused on taking share.
Intuitive Surgical, a California company that makes endoscopic instruments, is running higher along with heavy options activity amid takeover rumors.
Dow component and giant healthcare company--you really can't lump it in with big pharma because it sells drugs, medical devices and consumer products--Johnson & Johnson reported earnings this morning.
Boston Scientific is fighting to break out of its recent trading range as a large block of puts changes hands. BSX opened today by more than 2 percent from its close of $7.60 yesterday... The put activity coincides with a company setback in its protracted court battle with Johnson & Johnson.
The Dow fell for the fourth day in a row as concerns about massive losses at Citigroup knocked its shares 17 percent lower, dragging down bank stocks...
Options traders Tuesday are betting on more upside in medical technology company Stryker. Following heavy volume yesterday, SYK continues to see activity at the January 40 calls...
Cramer makes the call on viewers' favorite stocks.
Things look worse for GM, Ford and Chrysler Wednesday as Congress seems less likely to approve a $25 billion automaker bailout. Stocks slipped — but some analysts say that slide had little to do with the Big 3. CNBC canvassed the experts, who foresee plunging oil prices, a stronger dollar — and say the market has already bottomed (!).
There are reports of booze, women and beads--as in Mardi Gras beads. Specifically, the piece cites allegations from a lawsuit brought by a former MDT attorney who says the medical device maker sponsored a "discussion group" outing to New Orleans.
A first-of-its-kind study shows that putting hundreds of thousands of American heart patients on drugs instead of giving them a stent could save the country billions of dollars a year.
Not too long ago, some had written off the potential for significant growth to resume in sales of the little wire mesh tubes that are painted with special drugs to help keep arteries from reclogging.
The Lightning Round is extended in this CNBC.com exclusive feature.
Even with the overall stock market struggling to post gains, there are always winners somewhere. Carter Worth reveals where!
Cory Scott is a second-semester MBA student at the Walton College of Business at the University of Arkansas. He's already wading into the tricky waters of managing investments. There's about $350,000 in his fund, the student-managed Shollmier Fund, and it's up an average of 7.5 percent per year over the last three years.
Following are the day’s biggest winners and losers. Find out why shares of Medtronic and Reliance Steel popped while Las Vegas Sands and Starbucks dropped.
Gerald Jordan, portfolio manager at Jordan Opportunity Fund said that investing in large cap stocks is the way to go.
Fast Money Now – the trades you need while the market is open.
A new study and an editorial in a major medical journal could reignite the debate over whether drugs or stents or a combination of both are better for the millions of Americans with heart trouble.